Upload
redchip-companies-inc
View
251
Download
3
Tags:
Embed Size (px)
DESCRIPTION
Aker october 2014 speaking presentation
Citation preview
October 2014
2
Forward Looking Statements All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Akers Biosciences, Inc. (ABI or the Company) products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited, to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights and other risks discussed in the Company’s registration statement on Form S-1 and other reports filed with the Securities and Exchange Commission which is available for review at www.sec.gov. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the Company's business. The Company disclaims any intent or obligation to update these forward-looking statements.
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
Introduction
• Bringing diagnostics to the point-of-care • Multiple core products with blockbuster potential • Faster, better diagnostics which take costs out of the
healthcare system
3 COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
4
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
Products Selling NOW
5
• Only FDA cleared test to detect heparin allergies; competes with expensive, slow turn-around laboratory tests
• 25 million patients in US and EU receive heparin annually
• 4 million tests performed annually in laboratories in US which could be replaced with
PIFA
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
STAT Point-of-Care
6
Only combined rapid test for Total, HDL and LDL cholesterol
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
7 COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
Research & Discovery
Clinical Development
Commercial Development
Launch & Market Entry
Pipeline products
Dengue Fever
Troponin 1
Chlamydia
Malaria
Diabetic Ketoacidosis
COPD
Lung Cancer
Asthma
8
Developing the world’s first rapid diagnostic assays for Lung Cancer Asthma & COPD through breath
• LUNG CANCER: > 1.6 million people diagnosed each year • ASTHMA: Up to 15% of a country’s population may have Asthma • COPD: 1 billion smokers at risk for COPD
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
9
Improving how diabetics manage Ketoacidosis
• Type 1, and some Type 2, diabetics are at risk for developing ketoacidosis (blood acid build-up)
• 3 million type 1 diabetics in US • Reduces healthcare costs by decreasing the need for hospital visits and
expensive lab testing
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
10
• Design and Development Agreement with Konica Minolta • Will be First 5-Minute POC test to detect marker of heart attack
• Nearly 1 million heart attacks each year in US
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
Point-of-Care
Improving the way Myocardial Infarction is Diagnosed
11
Milestones
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
• Enhance sales and marketing capabilities
• Expand US distribution of PIFA PF4 products • Expand international distribution of PIFA PF4 products: China, India, EU, S. America • Create US distribution channels for Tri-Cholesterol “Check”, METRON and VIVO
worldwide • Product launches/clinical trials - Breath Ketone “Check” - PIFA Chlamydia Breath Asthma “Check” Breath Lung Cancer “Check” Breath COPD “Check”
• New healthcare environment demands cost-containment
• Multiple products with blockbuster potential already selling
• Substantial new product pipeline with mass market potential
12
Summary
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
Appendix
14
Profit and Loss
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
Six Months Fiscal Year Ended Jun 30 Ending Dec 31
2014 2013 2012
Revenue $2,527,076
$3,577,851
$1,564,101
Gross Profit 1,781,344
1,664,007
556,150
Administrative Expenses 1,670,728
1,524,626
1,493,707
Sales & Marketing Expenses 607,707
684,720
638,732
Research & Development Expenses 502,489
1,006,800
900,380
Operating Profit (1,128,867)
(1,526,773)
(2,725,228)
Net Profit (1,090,595)
(1,526,773)
(2,557,820)
15
Balance Sheet Overview
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
As of
Jun 30, 2014 Dec 31, 2013
Total Assets 17,773,670 6,075,622
Total Liabilities
1,110,437
1,953,388
Total Equity
16,663,233
4,122,234
16
Capitalization Structure
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
June 30, 2014 Shares
Common Shares 4,894,837
Directors & Officers Options – Exercise Price of $5.50 115,000
Key Employee Options – Exercise Price of $3.98 60,000
Warrants – Exercise Price of $71.76 1,989
Total – Fully Diluted 5,071,826
17
Experienced, Focused Management and Board
Raymond F. Akers, Jr. Ph.D. Founder, Executive Chairman of the Board (Director) • 30+ years in medical diagnostics; founded ABI in 1989 • Invented most of ABI’s products and technologies; numerous patents • Ph.D. in Neurochemistry, Northwestern University
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
Edwin C. Hendrick Executive Vice President, Sales and Marketing • 25 year career in healthcare leading the commercial aspects of
diagnostic and healthcare services companies ranging in size from $10 million to $1 billion in revenues; joined ABI in 2014
• Most recent engagements include executive positions with PLUS Diagnostics , US Labs and Ventana Medical Systems
Patrice Laterra McMorrow Vice President, Marketing • 20+ years in sales and marketing in diagnostics, pharmaceutical,
and ophthalmic industries; joined ABI in 2004 • Competencies: new product launches, sales operations, and
distribution management
Officers & Key Management Team
Gary M. Rauch Vice President, Finance • 35+ years in accounting, information systems, and operations
consulting, joined ABI in 2010 • Engagements in healthcare, manufacturing and distribution
Non-Executive Directors
Gavin E.D. Moran • Extensive experience in trading, finance and marketing • Trading roles at Shell International, Trafigura Ltd, and since
April 2010, beneficial shareholder at Sono International Ltd
Thomas J. Knox • Expertise in health care and finance • Former CEO of United Healthcare of Pennsylvania; Former
Chairman of the Board and Chief Executive Officer of Fidelity Insurance Group, Inc.
• Currently Chief Executive Officer of Knox Consulting Group, Chairman of ORB Automotive Corporation, Ltd.
Brandon T. Knox • Experience incorporate finance and financial management • Currently wealth advisor at Raymond James
Nicolas Daurel Vice-President, Sales and Marketing, EMEA • 20+ years experience in international sales • Held similar positions with Trinity Biotech plc, Diagnositica
Stago, SA, Roche Diagnostics